• Latest Posts
In Depth 11 Sep 2023

Evolving biotech funding trends: VCs lead new series B deals, but early-stage deals require insider support

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

Exscientia IPO Attracts Tech Investor Bets to AI Drug Discovery

Update: ADC Therapeutics’ IPO Hits Above Target with €215M

Two Gene Therapy Players Launch IPOs on Stormy Stock Market


Evotec IPO Hints At Stabilizing Investor Interest In Biotech Stocks

Third-Generation DNA Sequencing Shines with Oxford Nanopore’s IPO

Delayed IPOs and Market Drops Batter Biotech Stocks

Pandemic Boosts Diagnostics Field with High Revenues and Acquisitions

Lava Therapeutics’ IPO Shakes Cancer Niche of Gamma Delta T Cells

€51M Nasdaq IPO Will Fund Centogene’s Rare Disease Diagnostics